• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT GMBH ALINITY I INSULIN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT GMBH ALINITY I INSULIN Back to Search Results
Model Number 04T7520
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 12/12/2019
Event Type  malfunction  
Manufacturer Narrative
Patient information: all available patient information was included.Additional patient details are not available.An evaluation is in process.A follow up report will be submitted when the evaluation is complete.
 
Event Description
The customer obtained a falsely elevated alinity i insulin result.Sample id (b)(6) generated a flagged result of >3000 uu/ml, diluted 1:100 8547.5 uu/ml and diluted 1:200 9093.2 uu/ml.The sample was tested on roche generating 4 uu/ml.No impact to patient management was reported.
 
Manufacturer Narrative
The reagent lot was provided by the customer and lot number was change from unknown to 03511lp27.Investigation of the customer's issue included a review of the complaint text, a search for similar complaints, retained kit testing of an alternate lot and review of manufacturing and labeling documentation.Review of complaint trending reports did not identify any trends for the alinity i insulin assay.Review of complaint activity for reagent lot 03511lp27 did not identify an increase in complaint activity.Return testing was not completed as returns were not available.Since reagent lot 03511lp27 expired on december 7, 2019, a representative reagent lot (05511lp30) was used to assess the performance of the assay.An internal insulin panel, which has known concentrations, was tested with the reagent lot.All specifications were met indicating the assay is performing acceptably.Manufacturing documentation for the reagent lot did not identify any issues associated with the complaint issue.Additionally, labeling was reviewed and sufficiently addresses the customer's issue.Based on the available information, no systemic issue or deficiency of the alinity i insulin assay was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ALINITY I INSULIN
Type of Device
INSULIN
Manufacturer (Section D)
ABBOTT GMBH
max-planck-ring 2
wiesbaden 65205
GM  65205
MDR Report Key9554488
MDR Text Key188321942
Report Number3002809144-2020-00013
Device Sequence Number1
Product Code CFP
UDI-Device Identifier00380740150815
UDI-Public00380740150815
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 01/30/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/06/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date12/07/2019
Device Model Number04T7520
Device Catalogue Number04T75-20
Device Lot Number03511LP27
Was Device Available for Evaluation? No
Date Manufacturer Received01/14/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ALINITY I PROCESSING MODULE,; ALINITY I PROCESSING MODULE,; LIST 03R65-01, SERIAL (B)(6); LIST 03R65-01, SERIAL (B)(6)
-
-